Treatment of Suspected Wilson's Disease

Diagnostic Confirmation

The American Association for the Study of Liver Diseases recommends a 24-hour urinary copper excretion test, expecting >100 µg/day, likely much higher in symptomatic disease, in patients with suspected Wilson's disease 2, 3
A slit-lamp examination for Kayser-Fleischer rings is recommended, although it may be absent in purely hepatic presentations, especially in children 2, 4
Hepatic copper quantification is recommended if liver biopsy is safe, with an expected value >250 µg/g dry weight, and a diagnostic threshold >200 µg/g 2
The calculation of non-ceruloplasmin bound (free) copper is recommended, with an expected value >25 µg/dL in untreated Wilson's disease 5, 2
ATP7B genetic testing is recommended to confirm diagnosis and facilitate family screening 2, 3

The American Association for the Study of Liver Diseases recommends starting intensive induction regimen immediately with temporally separated dosing to prevent chelator-zinc binding, using trientine and zinc 1
Trientine is preferred over D-penicillamine in children due to lower risk of neurological worsening and fewer severe side effects, with a recommended dose of 20 mg/kg/day rounded to nearest 250 mg, divided into 2-3 doses 6, 5
Zinc acetate is recommended at 25 mg elemental zinc three times daily, given at least 5-6 hours separated from trientine doses, and taken on an empty stomach for optimal absorption 8, 9

Baseline testing before treatment should include complete blood count, comprehensive metabolic panel, INR/PT, 24-hour urinary copper, and urinalysis 5, 2, 3
Monitoring during treatment should include weekly CBC, urinalysis, and liver function tests for the first 2-4 weeks, and every 2-4 weeks thereafter, with adjustments as needed 5, 2
Common pitfalls to avoid include using D-penicillamine as first-line treatment, giving chelator and zinc simultaneously, allowing zinc to be taken with food, and discontinuing treatment even briefly 5, 1, 8, 9

Urgent referral to a liver transplant center is recommended for patients with decompensated Wilson's disease, with features suggesting high risk for treatment failure, such as significant coagulopathy, hyperbilirubinemia, and history of recurrent jaundice 1, 3
Prognostic scoring using the Nazer criteria can predict the need for transplantation, with a score ≥7 indicating a high risk 1

Improvement in synthetic function, reduction in bilirubin, and clinical improvement in jaundice and ascites are expected within 2-6 months of treatment 5
Continued recovery and normalization of free copper levels are expected within 6-12 months of treatment 6, 5
If no improvement or clinical deterioration occurs, urgent liver transplantation is recommended 1, 3

Once stabilized, transition to maintenance monotherapy with either trientine or zinc is recommended, with lifelong treatment being mandatory to prevent fatal hepatic decompensation 6, 7, 5, 1
Dietary copper restriction and monitoring every 3 months indefinitely are also recommended, with screening of siblings for Wilson's disease 7, 5, 2, 3